Loading patent…
AssigneesUniversity of Maryland, Baltimore, Board of Regents, The University of Texas System, Sanford-Burnham Medical Research Institute
InventorsAlexander Mackerell, Jr., Hong Zhang, Andrei Osterman, Rohit Kolhatkar
Estimating the term…
The emergence of multidrug-resistant pathogens necessitates the search for new antibiotics acting on previously unexplored targets. Nicotinate mononucleotide adenylyltransferase of the NadD family, an essential enzyme of NAD biosynthesis in most bacteria, was selected as a target for structure-based inhibitor development. To this end, the inventors have identified small molecule compounds that inhibit bacterial target enzymes by interacting with a novel inhibitory binding site on the enzyme while having no effect on functionally equivalent human enzymes.
A pharmaceutical composition comprising Compound 01—02 as an active ingredient and a pharmaceutically acceptable carrier or excipient:
A pharmaceutical composition comprising at least one compound of Formula 1 as an active ingredient and a pharmaceutically acceptable carrier or excipient:
Dependencies are inferred from the claim text.